Sun Pharmaceutical Industries has submitted a binding all‑cash offer worth $12 billion for Organon & Co., marking the largest overseas acquisition bid by an Indian pharmaceutical company to date.
The offer is all‑cash and binding, with Sun Pharma already securing financing commitments from JPMorgan, MUFG, Standard Chartered and Citi. The transaction is expected to close within the next few weeks, pending regulatory approvals and shareholder consent.
Sun Pharma’s strategy is to transition from a generics‑focused business to a branded, innovation‑driven pharmaceutical company. Acquiring Organon, which owns a portfolio of women’s health products, biosimilars and established brands, provides the scale and product mix needed to accelerate that shift.
Organon has been aggressively deleveraging, reducing its debt from $9.5 billion at spin‑off to $8 billion by the end of 2025, leaving a net debt of $8.16 billion. Revenue fell 3% in 2025 to $6.2 billion, and earnings per share dropped from $0.90 to $0.63, reflecting a 30.7% adjusted EBITDA margin and a 1% decline in women’s health revenue driven by pricing pressure and competition.
Following the announcement, Organon’s stock surged as investors priced in the premium offer, while Sun Pharma’s stock fell as market participants weighed the size and leverage of the deal. The transaction would provide Organon shareholders with a significant exit premium and help relieve the company’s debt burden.
If the deal is completed, it will create a substantial ownership change, accelerate Sun Pharma’s move into branded pharmaceuticals, and give Organon the capital to continue its debt‑reduction program. Regulatory approvals and shareholder consent remain required for the transaction to close.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.